These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 14557343)

  • 21. [Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
    MMW Fortschr Med; 2003 Oct; 145(44):42-3. PubMed ID: 14655506
    [No Abstract]   [Full Text] [Related]  

  • 22. Role of the selective aldosterone receptor blockers in arterial hypertension.
    Sierra C; Ruilope LM
    J Renin Angiotensin Aldosterone Syst; 2004 Mar; 5(1):23-5. PubMed ID: 15136969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aldosterone blockade in post-acute myocardial infarction heart failure.
    Pitt B; Ferrari R; Gheorghiade M; van Veldhuisen DJ; Krum H; McMurray J; Lopez-Sendon J
    Clin Cardiol; 2006 Oct; 29(10):434-8. PubMed ID: 17063946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Late breaking heart failure trials from the 2003 ACC meeting: EPHESUS and COMPANION.
    Teerlink JR; Massie BM;
    J Card Fail; 2003 Jun; 9(3):158-63. PubMed ID: 12815564
    [No Abstract]   [Full Text] [Related]  

  • 25. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.
    Iqbal J; Parviz Y; Pitt B; Newell-Price J; Al-Mohammad A; Zannad F
    Eur J Heart Fail; 2014 Feb; 16(2):143-50. PubMed ID: 24464876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
    Pitt B; Williams G; Remme W; Martinez F; Lopez-Sendon J; Zannad F; Neaton J; Roniker B; Hurley S; Burns D; Bittman R; Kleiman J
    Cardiovasc Drugs Ther; 2001 Jan; 15(1):79-87. PubMed ID: 11504167
    [No Abstract]   [Full Text] [Related]  

  • 27. Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist.
    Verma A; Solomon SD
    Curr Heart Fail Rep; 2007 Dec; 4(4):183-9. PubMed ID: 18221614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.
    Keating GM; Plosker GL
    Drugs; 2004; 64(23):2689-707. PubMed ID: 15537370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aldosterone target organ protection by eplerenone.
    Rudolph AE; Rocha R; McMahon EG
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):229-38. PubMed ID: 15134822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH; Abuissa H; Pitt B
    Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
    Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure.
    Mottram PM; Haluska B; Leano R; Cowley D; Stowasser M; Marwick TH
    Circulation; 2004 Aug; 110(5):558-65. PubMed ID: 15277317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Aldosterone and aldosterone antagonists. Eplerenone in cardiac insufficiency after myocardial infarction].
    Heinzl S
    Med Monatsschr Pharm; 2005 Mar; 28(3):76-9. PubMed ID: 15794365
    [No Abstract]   [Full Text] [Related]  

  • 35. Aldosterone antagonists in heart failure.
    Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P
    J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances.
    Galuppo P; Bauersachs J
    Eur J Clin Invest; 2012 Oct; 42(10):1112-20. PubMed ID: 22536780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials.
    Rossello X; Ariti C; Pocock SJ; Ferreira JP; Girerd N; McMurray JJV; Van Veldhuisen DJ; Pitt B; Zannad F
    Clin Res Cardiol; 2019 May; 108(5):477-486. PubMed ID: 30264282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials.
    Ezekowitz JA; McAlister FA
    Eur Heart J; 2009 Feb; 30(4):469-77. PubMed ID: 19066207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease.
    Pitt B; Stier CT; Rajagopalan S
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):164-8. PubMed ID: 14608520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Left ventricular dysfunction: causes, natural history, and hopes for reversal.
    Armstrong PW
    Heart; 2000 Sep; 84 Suppl 1(Suppl 1):i15-7:discussion i50. PubMed ID: 10956313
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.